Suzhou Fushilai Pharmaceutical Co., Ltd. Stock: price and insider trades · China
富士莱
Suzhou Fushilai Pharmaceutical Co., Ltd.: what insiders have been doing
Suzhou Fushilai Pharmaceutical Co., Ltd. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). From 6 November 2025 to 6 November 2026, the disclosure feed for Suzhou Fushilai Pharmaceutical Co., Ltd. logged 1 filing by 1 insider.
The flow runs one way only: 1 sale worth €14k, from 1 insider, and no purchase. Biggest ticket of the year: €14k, sold by 陆建刚 and made public on 1 June 2026.
Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (521 companies, median 2 filings), a count of 1 filing is below the norm. Our records for Suzhou Fushilai Pharmaceutical Co., Ltd. go back to 2023, with no purchases and 3 sales on the open market in total.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About Suzhou Fushilai Pharmaceutical Co., Ltd.
富士莱 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It specializes in the development and distribution of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
